Shots:

• The P-I BE study involves assessing of PK limitations i.e. Cmax- AUC for Xspray’s leading product HyNap-Dasa formulated vs Sprycel (Dasatinib)
• The P-I study (N=16) with healthy candidates administrating single dose of each product- demonstrated positive results while confirming the validity of Xspray's patented formulation technology
• The results will be helpful in designing of planned registration study for ANDA application of HyNap-Dasa

Ref: PRNewswire | Image: Xspray Pharma